In this retrospective analysis, researchers studied adult patients who were diagnosed with non-metastatic breast cancer and received GLP1-RAs for at least 3 months.
Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.
FDA Commissioner Dr Marty Makary and his top deputy, Dr Vinay Prasad, detailed the plan Feb. 18 in The New England Journal of Medicine. The move is the latest in a series of FDA efforts to eliminate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results